[1]
Solanki RK, Singh P, Midha A, Chugh K. Schizophrenia: Impact on quality of life. . Indian J Psychiatry 2008; 50(3): 181-6.
[2]
Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. Lancet Psychiatry 2016; 3(2): 171-8.
[3]
Thara R. Schizophrenia - Enhancing hope with better care & research. Indian J Med Res 2014; 140(4): 469-71.
[4]
Caccia S, Pasina L, Nobili A. New atypical antipsychotics for schizophrenia: Iloperidone. Drug Des Devel Ther 2010; 4: 33-48.
[5]
Tonin FS, Wiens A, Fernandez-Llimos F, Pontarolo R. Iloperidone in the treatment of schizophrenia: An evidence-based review of its place in therapy. Core Evid 2016; 11: 49-61.
[6]
Lahon K, Shetty HM, Paramel A, Sharma G. A retrospective study of extrapyramidal syndromes with second generation antipsychotics in the psychiatric unit of a tertiary care teaching hospital. J Pharmacol Pharmacother 2012; 3(3): 266-8.
[7]
Luft B, Taylor D. A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. Expert Opin Pharmacother 2006; 7(13): 1739-48.
[8]
Chadda RK, Ramshankar P, Deb KS, Sood M. Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients. J Pharmacol Pharmacother 2013; 4(3): 176-86.
[9]
Montes AB, Rey JA. Iloperidone (Fanapt): An FDA-approved treatment option for schizophrenia. P&T 2009; 34(11): 606-13.
[11]
Wilson AM, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol 2004; 57(2): 127-34.
[12]
Poluzzi E, Raschi E, Piccinni C, De Ponti F. Data mining techniques in pharmacovigilance: Analysis of the publicly accessible FDA adverse event reporting system (AERS). Data mining applications in engineering and medicine: InTech; 2012.
[13]
Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA Adverse Event Reporting System. . Int J Med Sci 2013; 10(7): 796-803.
[14]
Bate A, Lindquist M, Edwards IR, Orre R. A data mining approach for signal detection and analysis. Drug Saf 2002; 25(6): 393-7.
[15]
Crabtree BL, Montgomery J. Iloperidone for the management of adults with schizophrenia. Clin Ther 2011; 33(3): 330-45.
[16]
Sears E, Brooks S. New drugs approved in 2009. Proceedings (Baylor University Medical Center) 2010; 23(2): 175-83.
[17]
Scarff JR, Casey DA. Newer oral atypical antipsychotic agents: A review. P&T 2011; 36(12): 832-8.
[18]
Citrome L. Iloperidone: Chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol 2010; 6(12): 1551-64.
[19]
Kumar R, Sachdev PS. Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry 2009; 22(3): 293-9.
[20]
Abbott C, Jaramillo A, Wilcox C, Hamilton D. Antipsychotic drug effects in schizophrenia: A review of longitudinal fmri investigations and neural interpretations. Curr Med Chem 2013; 20(3): 428-37.
[21]
Zeng C, Zhang M, Asico LD, Eisner GM, Jose PA. The dopaminergic system in hypertension. Clin Sci 2007; 112(12): 583-97.
[22]
Ng B, Postlethwaite A, Rollnik J. Peripheral oedema in patients taking olanzapine. . Int Clin Psychopharmacol 2003; 18(1): 57-9.
[23]
Umar MU, Abdullahi AT. Self-limiting atypical antipsychotics-induced edema: Clinical cases and systematic review. . Indian J Psychol Med 2016; 38(3): 182-8.
[24]
Rodriguez-Cabezas LA, Kong BY, Agarwal G. Priapism associated with iloperidone: A case report. Gen Hosp Psychiatry 2014; 36(4): 451.e5-6.
[25]
Hosseini SH, Polonowita AK. Priapism associated with olanzapine. PJBS 2009; 12(2): 198-200.
[26]
Park YW, Kim Y, Lee JH. Antipsychotic-induced sexual dysfunction and its management. World J Mens Health 2012; 30(3): 153-9.
[27]
Bégaud BB. Dictionary of pharmacoepidemiology. John Wiley & Sons, Ltd 2002; pp. 15-22.
[28]
Pariente A, Gregoire F, Fourrier-Reglat A, Haramburu F, Moore N. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: The notoriety bias. Drug Saf 2007; 30(10): 891-8.
[29]
Weber JCP. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. In: Rainsford KD, Velo GD, Eds. Side-effects of anti-inflammatory drugs, advances in inflammation research. Raven Press: New York 1984; pp. 1-7.
[30]
Weber JCP. Epidemiology in the United Kingdom of adverse drug reactions from non-steroidal anti-inflammatory drugs. In: Rainsford KD, Velo GP, Eds. Side-Effects of anti-inflammatory drugs: Part one clinical and epidemiological aspects. Dordrecht: Springer Netherlands 1987; pp. 27-35.